Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials

IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM). Traditional treatments address symptoms but not the underlyin...

Descripció completa

Dades bibliogràfiques

Autors principals:	Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-01-01
Col·lecció:	Frontiers in Cardiovascular Medicine
Matèries:	hypertrophic cardiomyopathy cardiac myosin inhibitors mavacamten aficamten LVOT obstruction
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fcvm.2024.1477487/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!